For almost every disease, there are clinical trials that are frequently ongoing. These are the foundations upon which new kinds of medications and treatment regimens are developed, including those for breast cancer.
These trials allow for new therapeutic methods and medicines to be tested against several breast cancer variants in different demographics. They also provide the opportunity for people with the disease to have access to cutting-edge and potentially life-saving treatment.
There are currently several breast cancer treatments that have been used for years with relatively good results. However, many new treatments hold a great deal of promise due to the ever-increasing information available to researchers and scientists.
In this article, we go over why you might want to know about the newest treatments for breast cancer and how Ciitizen can help you get into them.
What are the newest breast cancer treatments?
Most of the most recent advancements in breast cancer research and treatment are only accessible by signing up through clinical trials. From the data available, many of these show promise in treating this disease effectively and enabling people to return to their normal daily routine.
Here are a few of the newest treatments for breast cancer. The more options that people with breast cancer have, the better.
- Trodelvy: This is the brand name for sacituzumab govitecan-hziy, a medication that received full approval from the FDA in April 2021. It is one of the newest treatments for breast cancer. This medication is approved for the treatment of metastatic triple-negative breast cancer in those who have had two other systemic therapies prior. This is one of the most difficult forms of breast cancer to treat, so Trodelvy provides hope for many people. The ASCENT study showed that the medication lengthened the overall time of survival to nearly a full year, as opposed to just under seven months with chemotherapy.
- Phesgo: This medication consists of pertuzumab, trastuzumab, and hyaluronidase-zzxf. These all come together to form a medication that can be injected under the skin for the treatment of HER-2 positive breast cancer. The injectable route means that Phesgo could be administered at home by a qualified professional. It can be used after surgery in its early stages to reduce the risk of recurrence or before surgery when early-stage or locally advanced. For metastatic breast cancer, Phesgo can be combined with docetaxel in those who have yet to receive any kind of medication for metastasis. Phesgo was approved by the FDA in June 2020.
- Tukysa: Tukysa, the brand name for tucatinib, is another drug that is used to treat advanced HER-2 positive breast cancer. Approximately one in every five people with breast cancer has an HER-2 positive variant. Tukysa is approved to be used in combination with trastuzumab and capecitabine for HER-2 positive breast cancer that cannot be surgically removed or has metastasized. The addition of tucatinib to the other two medications was found during a clinical trial to increase the amount of time that the tumor did not grow by two months.
- Nerlynx: This is the brand name for the medication neratinib. It was approved by the FDA in February 2020 to be used in combination with capecitabine to treat advanced or metastatic HER-2 positive breast cancer. This combination is intended for patients who have received two metastatic HER-2 treatment regimens prior. At the end of the ExteNET trial, it was also found that the risk of brain and spinal cord recurrences was reduced in patients on Nerlynx.
- TARGIT-IORT: Unlike the other treatments on this list, TARGIT-IORT stands for targeted intraoperative radiotherapy. While it is not a new treatment, having been around since 2000, a long-term study released in late 2020 was able to provide clinical backing for its efficacy. This process involves radiation being targeted directly to the breast tissue following the resection of an early-stage tumor. It was found to be a good alternative to external beam radiation therapy regarding recurrence, while being cheaper and not requiring follow-up visits.
- Keytruda: In November 2020, Keytruda, the generic name of which is pembrolizumab, was approved by the FDA for the treatment of triple-negative breast cancer that is either metastatic or locally unresectable and recurrent. However, it specifically targets tumors that express the PD-L1 protein. The period with no growth of the tumor was increased by over four months compared to those using chemotherapeutic treatments, such as paclitaxel, with a placebo.
How can Ciitizen help?
At Ciitizen, we aim to keep all your health records in a single place, so they are easy to access and complete. You will find that applying for clinical trials is easier and faster than ever. This solution means you’ll never miss out on the newest treatments for breast cancer, and such opportunities can be lifesaving.
Your information will always be safe in our hands. Dealing with breast cancer is a monumental task on its own, so with Ciitizen, worrying about your health information and its safety is not something else that you’ll need to go through.
All these new treatments have been made possible due to regular patients subscribing to the clinical trials. Ciitizen will make it easier for you to be one of them.
Ciitizen is a free service that helps patients get more out of their health records. Our platform enables patients to find better treatment options and gives them the opportunity to advance the research for cures. Ready to control all of your medical records in one place? Sign up today in less than 5 minutes!